{"summary":"I specialize in Targeted Oncology, driving BioPharma, Health Systems and VC portfolio strategies and commercialization. I inject commercial insights into bench-to-clinic & bench-to-market drug development. I have led 3+ Biologics launches with double-digit growth and transitioned 11 Oncology products into PhI\/2 & 8 proof-of-concept entrants in Fortune 500 companies. \n\nExamples of portfolio strategy, commercialization, and product planning activities I have led:\n\n\ud83d\udd37 Led cross-functional commercial strategy for 25 Oncology Pipeline Programs across multiple \n     tumors, guiding the Companion Diagnostics Commercialization Strategy - transitioned 11 \n     Oncology products into Ph I and 8 into proof-of-concept  \n\ud83d\udd37 Led Companion diagnostics Commercial Strategy and Oncology Pipeline strategy for 200+ tests, \n     supporting launches of pioneering lung cancer drugs Zelboraf\u00ae and Xalkori\u00ae \n\ud83d\udd37 Pioneered the build of a commercial Precision Medicine Division for enhanced commercial input \n      into early R&D and clinical targeted therapy decision-making \n\ud83d\udd37 Led launch strategy for patient segments for a $300MUSD HEM\/ONC injectable delivery device \n      with 2-fold increase in market share within 18 months\n\ud83d\udd37 Developed a precision medicine launch playbook and contributed to US commercial launches\n      including $150M Oncology asset (BALVERSA\u00ae), with 21% 5Y CAGR\n\nAs a woman entrepreneur and lifelong STEM learner, I am passionate about supporting other women launch, grow and scale their businesses through mentoring, networking and fundraising. I am an active member of Bio NJ and a proud supporter and review board member at MassBio\u2019s Mass Life Sciences Women\u2019s Health Initiative.  \n\nReach out if you'd like to connect!","pastPositions":[{"endedOn":{"month":3,"year":2003},"companyName":"Bayer HealthCare Manufacturing S.r.l.","title":"Oncology Scientist, Early Pipeline Drug Discovery","companyUrn":"urn:li:fs_salesCompany:56825721","posId":1,"current":true,"startedOn":{"month":6,"year":2001}}],"lastName":"Ramsagar","objectUrn":"urn:li:member:4744396","geoRegion":"Morristown, New Jersey, United States","fullName":"Sangeetha Ramsagar","firstName":"Sangeetha","currentPositions":[{"companyName":"Kronos Health","description":"Kronos Health partners with Biotech and Pharma in:\n\u27a1\ufe0fBench-to-Market Early Development, Early to Late Stage Commercialization and Collaboration \n\u27a1\ufe0fWe support stakeholder scoping, approach and messaging to draw collaborations\n\u27a1\ufe0fWe drive and evaluate business development partnerships, licensing, acquisitions or spin-offs\n\nCheck out our website for more info and reach out if we can help! www.kronos-health.com","title":"Founder and CEO, Biotech Portfolio Strategy & Bench-to-Market Commercialization ","companyUrnResolutionResult":{"employeeCountRange":"2-10","headquarters":{"geographicArea":"New Jersey","country":"United States","city":"Morristown"},"website":"https:\/\/www.kronos-health.com\/","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/kronos-health\/","industry":"Biotechnology Research"},"companyUrn":"urn:li:fs_salesCompany:100315229","tenureAtCompany":{"numMonths":9},"startedOn":{"month":9,"year":2023}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAABIZMwBvNmi0gwoPiVQLmpG9L-yieWCfQ8,NAME_SEARCH,nQaB)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1697731860252?e=1723075200&v=beta&t=zYUaxj-JwepS5AL8mfeFjcK1j5cu2guLN4AbzN-TR8E","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1697731860252?e=1723075200&v=beta&t=uPIxbT5A5Pdqovrid6MUQzNXQ7NpkhKhetZ0HVJM2SU","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1697731860252?e=1723075200&v=beta&t=CNoP0wVk1Mbxnv_maN3-QjTobCn4c4wRsj9voWXL8fc","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1697731860252?e=1723075200&v=beta&t=4w2Yiquk8ZYckxUjoQhNF03qC9T81nVwSNi74uRer3o","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E03AQGZVy2BK8Op0A\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{"websites":[{"$anti_abuse_annotations":[{"attributeId":97,"entityId":19,"sourceUrn":"urn:li:member:4744396"},{"attributeId":48,"entityId":19,"sourceUrn":"urn:li:member:4744396"}],"category":"COMPANY","dataSource":"LINKEDIN","url":"www.kronos-health.com"}],"socialHandles":[{"type":"TWITTER","name":"SangeethaRx","dataSource":"LINKEDIN"}]},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2009},"degree":"MBA","eduId":24553778,"schoolUrn":"urn:li:fs_salesSchool:3157","school":"urn:li:fs_salesSchool:3157","fieldsOfStudy":["Entrepreneurship & Innovation"],"schoolName":"New York University - Leonard N. Stern School of Business","startedOn":{"year":2007}},{"endedOn":{"year":2008},"degree":"MBA","eduId":28853289,"schoolUrn":"urn:li:fs_salesSchool:157273","school":"urn:li:fs_salesSchool:157273","fieldsOfStudy":["Leadership and Global Strategy"],"startedOn":{"year":2007}},{"endedOn":{"year":2001},"degree":"MS","eduId":16984956,"schoolUrn":"urn:li:fs_salesSchool:3173","school":"urn:li:fs_salesSchool:3173","fieldsOfStudy":["Cellular and Molecular Genetics"],"schoolName":"The Ohio State University","startedOn":{"year":1998}}],"skills":[{"numOfEndorsement":14,"name":"Global Portfolio Strategy"},{"numOfEndorsement":21,"name":"Strategy"},{"numOfEndorsement":45,"name":"Oncology"},{"numOfEndorsement":14,"name":"Precision Medicine Oncology"},{"numOfEndorsement":5,"name":"Market Analysis and Positioning"},{"numOfEndorsement":4,"name":"Due Diligence Evaluation"},{"numOfEndorsement":38,"name":"Business Development"},{"numOfEndorsement":9,"name":"New Business Development"},{"numOfEndorsement":14,"name":"Life Sciences"},{"numOfEndorsement":8,"name":"Business Case Preparation"},{"numOfEndorsement":16,"name":"Commercialization"},{"numOfEndorsement":10,"name":"Cross-functional Coordination"},{"numOfEndorsement":23,"name":"Management"},{"numOfEndorsement":12,"name":"Marketing Strategy"},{"numOfEndorsement":19,"name":"Business Strategy"},{"numOfEndorsement":34,"name":"Pharmaceutical Industry"},{"numOfEndorsement":10,"name":"Leadership"},{"numOfEndorsement":5,"name":"Medical Devices"},{"numOfEndorsement":6,"name":"Brand Management"},{"numOfEndorsement":14,"name":"Cross-functional Team Leadership"},{"numOfEndorsement":12,"name":"Product Launch"}],"numOfConnections":2394,"patents":[],"headline":"Founder and CEO Kronos Health | BioPharma Bench-to-Market \ud83e\uddea\ud83d\udcc8 Portfolio Strategy and Early Commercialization Executive  | Biomarker \ud83c\udfaf Commercial Strategy Expert | Board Member \ud83e\uddec","courses":[],"certifications":[{"companyUrn":"urn:li:fs_salesCompany:107223","url":"https:\/\/www.youracclaim.com\/badges\/60263aa0-2efc-4374-82f5-4cdbbdf0de84\/linked_in_profile","authority":"Prosci","name":"Prosci\u00ae Certified Change Practitioner","company":"urn:li:fs_salesCompany:107223","startedOn":{"month":4,"year":2020}},{"authority":"Rutgers Business School","name":"Health Policy Excellence","company":"urn:li:fs_salesCompany:4261","startedOn":{"month":10,"year":2018},"companyUrn":"urn:li:fs_salesCompany:4261"},{"authority":"The Center for Leadership Studies","name":"Situational Leadership","company":"urn:li:fs_salesCompany:80704","startedOn":{"month":2,"year":2010},"companyUrn":"urn:li:fs_salesCompany:80704"},{"authority":"Turning Point HCM","name":" Fractional Business Partner Certificate","company":"urn:li:fs_salesCompany:11519651","startedOn":{"month":2,"year":2024},"companyUrn":"urn:li:fs_salesCompany:11519651"}],"memberBadges":{"premium":true,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/sangeetharamsagar","organizations":[{"name":"Womensphere","description":"Womensphere is a global community platform and social enterprise dedicated to unleashing the potential of women and girls, inspiring transformational leadership and innovation, and mobilizing systemic interventions and individual initiatives to create a better future for our world. We form collaborations with leaders, innovators, companies, organizations, networks, and academic institutions around this shared purpose","position":"Global Advisory Board Member"},{"name":"New York Women in Science , Technology, Engineering and Mathematics (NY Wi STEM)","description":"http:\/\/nywistem.wordpress.com\/\n\nNew York Women in Science Technology Engineering and Mathematics (NYWiSTEM) is an organization that fosters a leadership, mentoring and networking incubator for Global graduates across various academic institutions and industries.\n\n","position":"Mentor and Speaker","startedOn":{"month":10,"year":2014}},{"name":"Hanson Wade (Biomarkers and Diagnostics Series)","description":"Speaker on Companion Diagnostics Commercialization; Led cross functional Workshops with senior executives across pharmaceutical and diagnostic companies; Opened dialogues with payors and regulatory functions around the challenges and solutions to next era of diagnostic products.\n\nhttp:\/\/world-cdx.com\/wp-content\/uploads\/sites\/65\/2014\/03\/World-CDx-Year-Book-2014.pdf\n\nhttp:\/\/world-cdx.com\/speaker\/sangeetha-ramsagar\/\n\nhttp:\/\/cdx-regulation.com\/about\/speakers\/\n\nhttp:\/\/www.nature.com\/natureevents\/science\/events\/35841-World_CDx_Boston_2015\n","position":"Moderator and Speaker World CDx","startedOn":{"month":1,"year":2013}}],"location":"Morristown, New Jersey, United States","publications":[],"positions":null,"posts":[{"createdAt":1717165140000,"insightId":"f911597f-0eb2-4dbd-92b0-e29a5c0ed881","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQFZVde3P6CxtQ\/feedshare-shrink_2048_1536\/0\/1717165165498?e=1720051200&v=beta&t=TmcgT2ajq98NRVNtxUJbCnzP4w6Qyqs7gYVqktueT18"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":6},{"type":"APPRECIATION","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7202312728588234752","threadUrn":"urn:li:activity:7202312728588234752","reactionsCount":7,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7202312727443193856","message":{"attributes":[{"start":587,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eQZAhkQb"}}},{"start":613,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bio2024"}}},{"start":622,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotechpharma"}}},{"start":637,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotechtrends"}}},{"start":652,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharmapartnerships"}}},{"start":673,"length":28,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:5190034"}}},{"start":702,"length":13,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:100315229"}}}],"text":"Connect with me in the BIO One-on-One Partnering system \n\n\u26a1 How are you preparing your product's adoption-readiness in your registration trial or investor approach?\n\u26a1 Do you have a go-to-market commercial plan and a differentiated collaborator approach?\n\u26a1 Are your portfolio choices aligning with pharma\u2019s strategic goals?\n\u26a1 How are you maximizing the revenue potential of your biotech assets?\n\nIf you are a private or public biotech company, or an investor looking to integrate early commercialization advice, let's connect. Early conversations often lead to disruptive ideas \ud83d\udcca\ud83e\udd1d\n \n\ud83d\udd17 https:\/\/lnkd.in\/eQZAhkQb\n\n#BIO2024 #BiotechPharma #BioTechTrends #PharmaPartnerships\n\nBIO International Convention KRONOS HEALTH"},"entityUrn":"urn:li:share:7202312727443193856"}}},{"createdAt":1716639060000,"insightId":"d7260ac0-8a54-47be-977c-6944a27eb523","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQEA2-mYJz22BQ\/articleshare-shrink_800\/0\/1716638264347?e=1717977600&v=beta&t=5ZMYeWi03ja_4q1Cw92rMQ8aUVw1galkYT_R4s9_27k","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQEA2-mYJz22BQ\/articleshare-shrink_800\/0\/1716638264347?e=1717977600&v=beta&t=5ZMYeWi03ja_4q1Cw92rMQ8aUVw1galkYT_R4s9_27k"}]},"resolvedUrl":"https:\/\/share.bio.org\/s\/6QgO7hvcrC2X62pVHUPKgw","title":"Register now"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":7},{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7200106309432602624","threadUrn":"urn:li:activity:7200106309432602624","reactionsCount":8,"commentsCount":3,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7200106308790829056","message":{"attributes":[{"start":10,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bio2024"}}},{"start":172,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bio2024"}}},{"start":181,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eQZAhkQb"}}},{"start":247,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bio2024"}}},{"start":256,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:lifesciences"}}},{"start":270,"length":23,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:innovationinhealthcare"}}},{"start":294,"length":22,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:strategicpartnerships"}}},{"start":317,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:commercialstrategy"}}},{"start":575,"length":13,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:100315229"}}}],"text":"Attending #BIO2024 in San Diego? Let's connect in the BIO One-on-One Partnering system. \n\nClick below to send Kronos Health\u00a0a meeting request in the BIO partnering system!\u00a0#BIO2024\nhttps:\/\/lnkd.in\/eQZAhkQb\n\nI look forward to seeing you in June!\n\n\n#BIO2024\n#lifesciences\n#innovationinhealthcare\n#strategicpartnerships\n#commercialstrategy\n\n___________________________________________\n\nIf you are an investor seeking external scouting and portfolio support \ud83d\udcca\ud83e\udd1d, or a biotech organization in need of stakeholder engagement, revenue influx, portfolio and commercial strategy \ud83d\udcc8, KRONOS HEALTH would like to evaluate a collaboration. \n\nLet's explore how I can help drive your goals."},"entityUrn":"urn:li:share:7200106308790829056"}}},{"createdAt":1712326560000,"insightId":"abc1ccb9-ace3-43f7-8a75-3114d3c2042d","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":5},{"type":"APPRECIATION","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7182018360581181440","threadUrn":"urn:li:activity:7182018360581181440","reactionsCount":6,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7182018359897526274","message":{"attributes":[{"start":9,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancerprevention"}}},{"start":31,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:earlydetection"}}},{"start":244,"length":25,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:743562"}}},{"start":294,"length":9,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:2243790"}}},{"start":304,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:29451093"}}},{"start":321,"length":19,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:141077021"}}},{"start":341,"length":26,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:92729644"}}},{"start":367,"length":19,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1584124"}}},{"start":387,"length":38,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:84936714"}}}],"text":"April is #CancerPrevention and #EarlyDetection month. Are you up to date with your screening plans? \n\n\ud83d\udd0dAre you an investor or a collaborator evaluating a Liquid Biopsy asset? Consider this: the article link is in the comments after the post.\n\nPrevent Cancer Foundation Naseem Sayani (she\/her) Alka Goel Kamala K Maddali Oriana Papin-Zoghbi Lung Cancer Policy NetworkGO2 for Lung Cancer International Society of Liquid Biopsy"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQGnP9_7_PBWVw\/feedshare-shrink_2048_1536\/0\/1712325131253?e=1720051200&v=beta&t=gL3jp-a39eqo-A5xVkpyfxzIU0DvMTXITHkr4AONq1M"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7182012148707905536","message":{"attributes":[{"start":360,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:ngs"}}},{"start":2294,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cancerprevention"}}},{"start":2314,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:earlydetection"}}},{"start":2421,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/e9y86Pbx"}}},{"start":2810,"length":27,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"mailto:sangeetha@kronos-health.com"}}}],"text":"\u00a0\ud83d\udd0dAre you an investor or a collaborator evaluating a Liquid Biopsy asset \ud83e\ude78? Consider this:\n\nRecent advances have propelled Liquid Biopsies to their full potential. Here are reasons why your team should be investigating liquid biopsy companies in your clinical or investment plans:\n\nSummarized from an Inside PMx article (link in comments) \n\n\ud83d\udc49In addition to #NGS, Droplet Digital PCR (ddPCR) has made precise characterization of low-abundance biomarkers in liquid biopsies possible, enabling absolute quantification of nucleic acid molecules\n\ud83d\udc49ctDNA analyses can offer deeper and more accessible insights into intra- and inter-tumor heterogeneity of solid tumors than traditional biopsy alone. This can also make up around 60-90% of the total circulating DNA in the blood\n\ud83d\udc49Increase in usage by clinical practice is closing the gap in standardization in sample collection, processing, and analysis methods, which can affect the reliability and reproducibility of results\n\ud83d\udc49Comfort level by clinicians has increased in leveraging liquid biopsies as a screening tool to assess both pre-adjuvant and primary treatment efficacy\n\n\nCase(s) in point:\n\n\u27a1\ufe0fIn the recent CHRONOS trial, use of ddPCR technology guided second-line treatment selection for metastatic colorectal cancer patients, allowing for anti-EGFR rechallenge in patients with wildtype RAS\/RAF\/EGFR mutations, providing a valuable alternative to standard late-line therapeutic options (limited efficacy and significant toxicities).\n\u27a1\ufe0fIn a \u201cplasma first\u201d study\u00a049 patients with radiological evidence of advanced lung cancer, 11 were able to begin targeted treatment based on NGS molecular testing of plasma samples prior to receiving molecular testing results from tissue biopsies. \n\u27a1\ufe0fThe median time to results for patients who underwent plasma ctDNA analysis was 9 days, compared to 25 days for standard-of-care tissue tests\n\nSpotlight:\n\n\ud83d\udc49Nucleosomes, released from cells undergoing apoptosis, may serve as more sensitive cancer biomarkers compared to ctDNA, as they are more stable in the blood\n\nIn addition to what you are detecting (cfDNA, EVs, Proteins, Nucleosomes) based on the disease area, What technology is used to detect it (ELISA, Proteomics, PCR, MassSpec)? Do you have a strong commercial value proposition? \n\nApril is #CancerPrevention & #EarlyDetection month. Are you up to date with your personal preventive and screening plan? \n\nArticle \ud83d\udd17 : https:\/\/lnkd.in\/e9y86Pbx\n\u00a0\n\u00a0\n______________________________________________________________________________\nFind this useful? Follow us, hit the \ud83d\udd14 \n\nAt Kronos, we support teams with bench-to-market portfolio strategy, market assessment, early commercialization strategy, stakeholder pitch approach, and business development. \n\nIf you want an initial intake and analysis of your needs, DM sangeetha@kronos-health.com\n\u00a0"},"entityUrn":"urn:li:share:7182012148707905536"},"entityUrn":"urn:li:share:7182018359897526274"}}},{"createdAt":1712232180000,"insightId":"e19210aa-89b0-4521-a16d-221f3cb049d1","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Top Leadership Voice "},"mediaType":"PAGINATEDDOCUMENT"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":22},{"type":"PRAISE","count":1},{"type":"APPRECIATION","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7181622483949625345","threadUrn":"urn:li:ugcPost:7181622483949625345","reactionsCount":24,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181622483949625345","message":{"attributes":[{"start":227,"length":8,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1337"}}},{"start":847,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:gratitude"}}},{"start":858,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:innovation"}}},{"start":870,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:leadership"}}}],"text":"Every day, I aim to bring you added value, whether you want to grow your Biotech organization, navigate your personal growth, or build your leadership team. So, I am extremely humbled to be considered a Top Leadership Voice on LinkedIn. While I'm unsure how I received this badge, I am grateful for those who took the time to nominate me. Thank you for recognizing my contributions and for your continued support.\n\nHaving returned from a multi-city South Asia tour and met with innovative organizations, CSR sustainability sites, and Venture Capital investors, the value of cross-border cross-industry networks was validated\u2014now more than ever. \n\nIf you do things the way they were always done using the same principles, you are sure to land in the same spot all over again! Innovation and leadership grow stronger through new ways of thinking. \n\n#gratitude #innovation #leadership"},"entityUrn":"urn:li:ugcPost:7181622483949625345"}}},{"createdAt":1712137920000,"insightId":"defb52d6-b184-4d31-bb1b-5d81737dd248","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQGLiqm6HHXgpA\/feedshare-shrink_2048_1536\/0\/1712137966643?e=1720051200&v=beta&t=2xPuIzmiSPb6lHoAfl9428doQ-fJ8kE3-LfKCuzAwWE"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":26},{"type":"PRAISE","count":2},{"type":"INTEREST","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7181227128774889473","threadUrn":"urn:li:activity:7181227128774889473","reactionsCount":30,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7181227126937800704","message":{"attributes":[{"start":53,"length":15,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:76513439"}}},{"start":173,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biopharma"}}},{"start":202,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:oncology"}}},{"start":241,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:clinicaltrials"}}},{"start":335,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":1053,"length":16,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:7131"}}},{"start":1098,"length":29,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:86940169"}}},{"start":1230,"length":21,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:60554016"}}},{"start":1252,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:430711914"}}},{"start":1294,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:144709243"}}},{"start":1307,"length":24,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:591855412"}}},{"start":1337,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:90419971"}}}],"text":"\ud83d\udca1Innovation\ud83d\udca1comes with new ways of thinking. \n\nThe Orbits Oncology team exemplifies innovative thinking with their competitive Digital Twin Organoid Platform, which helps #biopharma identify the best #Oncology drug candidates to move into #clinicaltrials.\n\nHere is why you want to take notice:\n\n\u27a1\ufe0fNot only do they have a competitive #drugdevelopment predictive platform with peer-reviewed publications, but they also integrate into current laboratory clinical platforms, making it an efficient, seamless process.\n\n\u27a1\ufe0fThey are the only digital platform that is facility- and device-agnostic for advanced organoid analysis, allowing integration into existing biopharma workflows at their point-of-need, using a platform-as-a-service model.\n\n\u27a1\ufe0fTheir proof of concept pilot showed a 20X faster turnaround time vs current standards, which is highly competitive with ongoing research. They aim to save up to $300MM in drug candidate research with their advanced precision modules, whereas translation typically breaks between bench and clinic.\u00a0Recognized by Nature Portfolio Publishing Journals and the Merck Digital Sciences Studio Orbits Oncology is bringing patients into the heart of drug discovery through the power of organoids. Ahmet Hamdi Cavusoglu Alexa Goldman\n\nKudos to the founding team Abraham Lin, Edgar Cardenas De La Hoz, and Tyler Gilcrest\n\nLooking forward to your continued success and growing collaborations!!"},"entityUrn":"urn:li:share:7181227126937800704"}}},{"createdAt":1711979820000,"insightId":"372ccddf-a4ce-4b74-b2ad-ea7d8fd84af2","activityUnion":{"postActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:multiPhoto:1000151631010"}},"socialMetadata":{"reactionTypeCounts":[{"type":"PRAISE","count":4},{"type":"APPRECIATION","count":1},{"type":"LIKE","count":39},{"type":"EMPATHY","count":3}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7180563917780193281","threadUrn":"urn:li:ugcPost:7180563917780193281","reactionsCount":47,"commentsCount":2,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7180563917780193281","message":{"attributes":[{"start":134,"length":34,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:91053315"}}},{"start":480,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:5181799"}}},{"start":712,"length":17,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:89223851"}}},{"start":734,"length":23,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:399913239"}}},{"start":779,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womenshealthcare"}}},{"start":816,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:5069900"}}},{"start":880,"length":9,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:142357558"}}},{"start":930,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:14285189"}}},{"start":1079,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eY_SJBZ5"}}},{"start":1301,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:517624"}}},{"start":1339,"length":19,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:3712058"}}},{"start":1376,"length":27,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:76886822"}}},{"start":1412,"length":22,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:6866"}}},{"start":1503,"length":15,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:13935084"}}},{"start":1549,"length":17,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:3690"}}},{"start":1659,"length":22,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:18338028"}}},{"start":1690,"length":18,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:35673055"}}},{"start":2069,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/etqmDKmK"}}},{"start":2104,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eucKGaaE"}}},{"start":2171,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:17773597"}}},{"start":2185,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:319836032"}}},{"start":2198,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:2584755"}}},{"start":2212,"length":15,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:9288438"}}},{"start":2228,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:1174250"}}},{"start":2242,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:networking"}}},{"start":2254,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:nycnetworking"}}},{"start":2269,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharma"}}},{"start":2277,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:sapcnetwork"}}},{"start":2290,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womenshealth"}}},{"start":2304,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womenshealthcare"}}},{"start":2322,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:empowerwomen"}}},{"start":2336,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:healthequality"}}}],"text":"\u2b50Having returned from a trip to India and met with Biotech and Venture Capital organizations, I would like to spotlight SAPC today \u2b50\n\nSouth Asian Pharmaceutical Council Inc. (SAPC) is a networking and professional development organization that has provided a platform to professionals in the pharmaceutical and allied industries since 2008.\n\nIt was an honor to have supported SAPC on their first industry panel event of 2024, focusing on Biotechnology and Innovation. Great panel Anshal Purohit. Grateful for the opportunity to have met with several leaders in the South Asian community and re-connected with friends and colleagues from the past. \n\nThe speakers covered a cross-section of topics from innovative Lime Therapeutics\u00a0CEO Shardule Shah, PhD, MBA, Med tech-focused on #womenshealthcare led by the dynamic Marissa Fayer, and Venture capital and investor perspectives by Suman Lal.\n\nInspired by the leadership of founder Mark J Stevens, SAPC has established a charitable foundation dedicated to improving access to health care for marginalized people in South Asia.\n\n\ud83d\udd17 https:\/\/lnkd.in\/eY_SJBZ5\n\nSouth Asian biotech executives, particularly those with backgrounds in engineering and medicine, have taken on prominent leadership roles at major U.S. biotechnology companies in recent years.\n\n\ud83d\udc49Samarth Kulkarni, has been the CEO of CRISPR Therapeutics, since 2017. \n\n\ud83d\udc49Reshma Kewalramani, MD FASN, CEO of Vertex Pharmaceuticals, making her the first female CEO of a large U.S. biotech company\n\n\ud83d\udc49Sanjay Mehrotra, CEO of semiconductor company Micron Technology since 2017. Prior to that, he co-founded and led SanDisk, a major flash memory company. \n\n\ud83d\udc49Sekar (Sek) Kathiresan, CEO of Verve Therapeutics, a biotech startup developing CRISPR-based therapies for cardiovascular disease. He previously held leadership roles at the Broad Institute and Massachusetts General Hospital. \n\n\ud83d\udd26Product Spotlight: NexCAR19, a CAR-T therapy created by an Indian Biotech, is roughly 1\/10th cheaper than US therapeutics, and some patients achieve complete remission.\n\nNature \ud83d\udd17 https:\/\/lnkd.in\/etqmDKmK\n\nSAPC \ud83d\udd17: https:\/\/lnkd.in\/eucKGaaE\n\nGreat to have connected: \/ re-connected: Ashish D. Pal Chandra Goda Vandana Singh Zia Rahman, PhD Pavan Bhalla\n\n#Networking #NYCNetworking #Pharma #SAPCNetwork #womenshealth #womenshealthcare #empowerwomen #healthequality"},"entityUrn":"urn:li:ugcPost:7180563917780193281"}}},{"createdAt":1711610400000,"insightId":"ece85609-cab4-4ef5-a51d-8f63a4ead636","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":8}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7179014502061875201","threadUrn":"urn:li:activity:7179014502061875201","reactionsCount":8,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7179014501533392896","message":{"attributes":[{"start":0,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:adcs"}}},{"start":6,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":23,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:duediligence"}}},{"start":37,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:oncology"}}}],"text":"#ADCs #drugdevelopment #duediligence #oncology"},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQGeRLV2-urlEg\/feedshare-shrink_2048_1536\/0\/1711610392779?e=1720051200&v=beta&t=eAVXbOM2VFZ57BSj7a9fWgBNsZbnFWa1ES_l-Yy5ifQ"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7179014322344329216","message":{"attributes":[{"start":64,"length":17,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:15622141"}}},{"start":97,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:adcs"}}},{"start":375,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biomarker"}}},{"start":1161,"length":15,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:163993"}}},{"start":1177,"length":6,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1304385"}}},{"start":1605,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/e3h8p36W"}}},{"start":1631,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":1648,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:precisiononcology"}}},{"start":1667,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:oncology"}}}],"text":"Shiny objects have blind spots as well\n \nIn the linked article, Targeted Oncology sheds light on #ADCs, while reducing off-target side effects, present tolerability challenges, requiring careful monitoring and management of ADC-specific toxicities\n\nImportant translational Due Diligence check boxes for ADCs :\n \n Have the cohorts with AEs been genomically analyzed for their #Biomarker profiles?\n \n \ud83c\udf08 Are the clinical data sets heterogeneous? Can you, as an investor, help expand the trial to more heterogeneous populations?\n \n\ud83e\udd1d Is there a collaboration with selected clinical sites on patient data insights? AI integration for trial management is a step up. This could help important cohort selection criteria and appropriate dose modifications. \n \n\ud83e\uddec\ud83e\ude78Can Biomarker tests utilized in the clinical trial setting be standardized across sites? Have the data sets been retained? Is an MRD process possible or has it been implemented (even better). Patients homogenous for UGT1A1*28 allele in Trodelvy's trials, had a 58% incidence of grade 3\/4 neutropenia compared with 49% who were heterozygous. Also think Elahere's FR\u03b1-positive test for testing methodology. Gilead Sciences AbbVie\n \n\u2696\ufe0fHas the SOC shifted and benchmarked in the TPP? Are SOC guidelines unmanageable due to quality measure incentives? Think Zevalin and Retuxan!\n\nNot all ADCs are the same and ADC toxicities can vary widely\n\nTarget differentiation, testing methodologies and incorporation of genomics in cohort analysis are three critical steps that can make or break your ADC translational strategy and due diligence. \ud83d\udd0d\ud83d\udcc8\n\nArticle \ud83d\udd17: https:\/\/lnkd.in\/e3h8p36W\n\n#drugdevelopment #precisiononcology #oncology\n\n---\nKronos Health provides consulting services to biopharma for bench-to-market strategy. If you'd like to discuss your translational strategy, if you are either preparing for a registration trial or a investor\/stakeholder approach send us a message"},"entityUrn":"urn:li:share:7179014322344329216"},"entityUrn":"urn:li:share:7179014501533392896"}}},{"createdAt":1711452540000,"insightId":"8368a23b-d285-431c-9255-b67aed99953b","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4D22AQHhSfbq5s33JQ\/feedshare-shrink_2048_1536\/0\/1711452545585?e=1720051200&v=beta&t=GMo6-F-EgF1p0w_F6FCDDUee7R2c_1AI9iy33lePVfQ"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":18},{"type":"PRAISE","count":1},{"type":"INTEREST","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7178352263780843522","threadUrn":"urn:li:activity:7178352263780843522","reactionsCount":20,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7178352262778339329","message":{"attributes":[{"start":1022,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/dxtZeBev"}}},{"start":1199,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biomarkers"}}},{"start":1211,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:clinicaltrials"}}},{"start":1227,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}},{"start":1244,"length":16,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:7131"}}},{"start":1261,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:precisionmedicine"}}}],"text":"Time for WGS and RWD to drive transformative clinical development\n\nThis Nature article provides insights into precision cancer care through whole-genome sequencing (WGS) within the UK National Healthcare System. These studies offer further evidence supporting genomics-driven transformative clinical trial re-design.\n\n\ud83d\udca1Early trial cohort linkage between Biomarkers, genes and outcomes for better survival analysis. Case in point, the recent approval of Elahere was extended by 2.5 years, driven by a strong Biomarker Strategy\n\n\ud83d\udee1\ufe0fBetter AE management and cohort selection early-on. Case in point, the FDA's recent guidance for RWD on important factors to consider when conducting non-interventional studies on drug and biological products.\n\n\u26a1 Drive more efficient and effective clinical trials with sustainable clinical outcomes post-launch. We have come too far along in genomic research not to leverage biomarker-driven science to select for inclusive and responsive cohorts that benefit the right patients \n\nArticle \ud83d\udd17https:\/\/lnkd.in\/dxtZeBev\n\n\ud83d\udc49Biomarkers and genomic analysis initiated earlier in clinical trial design can make or break a trial and leapfrog your clinical development pathway\n\n#biomarkers #clinicaltrials #drugdevelopment Nature Portfolio #precisionmedicine"},"entityUrn":"urn:li:share:7178352262778339329"}}},{"createdAt":1710201060000,"insightId":"98c79fa9-19f0-4eb0-8b66-5c9e21dd8f50","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Advanced Therapies in Solid Tumors - A New Era?"},"mediaType":"PAGINATEDDOCUMENT"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":7}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7173103147983196160","threadUrn":"urn:li:ugcPost:7173103147983196160","reactionsCount":7,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7173103147983196160","message":{"attributes":[{"start":96,"length":18,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:75881924"}}},{"start":163,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:prostatecancer"}}},{"start":284,"length":5,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:1486"}}},{"start":335,"length":20,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:17963574"}}},{"start":383,"length":23,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:163789"}}},{"start":481,"length":14,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bladdercancer"}}},{"start":1183,"length":12,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:18121493"}}},{"start":1238,"length":14,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:10037801"}}},{"start":1314,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:oncoly"}}},{"start":1323,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:pharma"}}},{"start":1331,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biotech"}}},{"start":1340,"length":13,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:100315229"}}}],"text":"Is there an appetite for Advanced Therapeutics in Oncology Solid Tumors? \n\n\ud83d\udcf0 Earlier this year Janux Therapeutics\u2019s candidates in metastatic castration-resistant #prostatecancer  cancer and late-stage solid tumors sent the San Diego\u2013based biotech\u2019s stock soaring 172%\n\n\ud83c\udfa3Followed by Merck\u2019s $680 million acquisition of T Cell engager Harpoon Therapeutics in January.\n\n\ud83e\uddecIn January, Ferring Pharmaceuticals Pharma launched the first CGT therapy in unresponsive non-muscle invasive #bladdercancer. 53% high-grade recurrence rate survival in patients with BCG unresponsive disease in the latest launched CGT in Bladder Cancer\n\nAdvances in research technologies have led to a sustained increase in solid tumor clinical trials in next-generation therapeutics. \n\nThere are a few key reasons for taking a second take:\n\n\u27a1\ufe0f Better adenoviral vector constructs for solid tumor membrane    \n      penetration\n\u27a1\ufe0f Advancements in highly tumor-specific targets, reducing off tumor, off target toxicities.\n\u27a1\ufe0f Focus on genes that encode proteins linked to T-cell exhaustion\n\u27a1\ufe0f Novel administration considerations and role in clinical workflow\n\nOther factors to be considered?\n\nPS: Slides made with Beautiful.ai. a great tool\nAnalytics and insights from Kognitic, Inc. \u2013 a cutting edge Oncology and Biomarker predictive platform\n\n#oncoly, #pharma #biotech\u00a0KRONOS HEALTH"},"entityUrn":"urn:li:ugcPost:7173103147983196160"}}},{"createdAt":1710081840000,"insightId":"bab47ff0-3ab0-4389-8264-0fe24f7d2297","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":11},{"type":"EMPATHY","count":1},{"type":"INTEREST","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7172603276096327681","threadUrn":"urn:li:ugcPost:7172603276096327681","reactionsCount":13,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7172603276096327681","message":{"attributes":[{"start":32,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:leadership"}}},{"start":44,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:mentorship"}}},{"start":56,"length":7,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:future"}}},{"start":64,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:goalsetting"}}},{"start":77,"length":8,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:958851830"}}}],"text":"Perspective is a powerful tool\n\n#leadership #mentorship #future #goalsetting Rub\u00e9n D."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"10 Visuals That Will Change The Way You Think"},"mediaType":"PAGINATEDDOCUMENT"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7172565706104815616","message":{"attributes":[{"start":479,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/dm_Wvui3"}}}],"text":"10 Visuals That Will Change The Way You Think\n\n1. We get what we ask for\n\n2. The reality of progress \n\n3. When you should take a break\n\n4. Not everyone starts in the same place\n\n5. The reality of hard things \n\n6. How to have effective work discussions \n\n7. How to tackle obstacles in life\n\n8. How we should view failure  \n\n9. Working when you\u2019re anxious  \n\n10. The power of a great manager\n\nInterested in startups and venture capital? Check my free newsletter for more insights:\nhttps:\/\/lnkd.in\/dm_Wvui3"},"entityUrn":"urn:li:ugcPost:7172565706104815616"},"entityUrn":"urn:li:ugcPost:7172603276096327681"}}},{"createdAt":1709913540000,"insightId":"5c5e31a2-9682-47ae-97c7-a30afa42ddef","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"5 Women's Health Initiatives You Should Know About"},"mediaType":"PAGINATEDDOCUMENT"}},"socialMetadata":{"reactionTypeCounts":[{"type":"PRAISE","count":7},{"type":"APPRECIATION","count":1},{"type":"LIKE","count":17},{"type":"EMPATHY","count":5}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7171897446371840001","threadUrn":"urn:li:ugcPost:7171897446371840001","reactionsCount":30,"commentsCount":4,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171897446371840001","message":{"attributes":[{"start":9,"length":23,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:internationalwomensday"}}},{"start":38,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womenshistorymonth"}}},{"start":317,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:community"}}},{"start":606,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:lifesciences"}}},{"start":620,"length":17,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:inspireinclusion"}}},{"start":638,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:dei"}}},{"start":643,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:vcfunding"}}},{"start":654,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:womensempowerment"}}},{"start":675,"length":34,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:981555"}}},{"start":712,"length":22,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:367949527"}}},{"start":735,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:175134711"}}},{"start":748,"length":17,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:76204440"}}},{"start":768,"length":23,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:3685377"}}},{"start":792,"length":18,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:97467082"}}},{"start":813,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:3215085"}}},{"start":828,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:49244873"}}},{"start":840,"length":16,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:29340824"}}},{"start":857,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:531027249"}}},{"start":880,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:69792745"}}},{"start":892,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:15952009"}}},{"start":907,"length":11,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:93159679"}}},{"start":919,"length":6,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:1133372"}}}],"text":"On this \u00a0#InternationalWomensDay, and #womenshistorymonth, I feel privileged to have learned about, engaged with, and continued my journey with some truly talented giving people and organizations. \n\nHere are 5 groups and resources that I have come to engage with and find out about that I am sharing with my LinkedIn #community \n\nWomen are 50-75 percent more likely than men to have an adverse drug reaction across all therapeutic indications. While some progress has been made, from increased female participation in clinical trials to women\u2019s health in general being better defined, more work remains. \n\n#lifesciences #inspireinclusion #dei #vcfunding\u00a0#womensempowerment\n\n\nMassachusetts Life Sciences Center | Katya Mantrova, MD PhD Ryan Mudawar\nEmmeline Ventures\u00a0|\u00a0Naseem Sayani (she\/her)\nShow Her The Money | Catherine Gray\nCarolee Lee Elizabeth Garner Haley Walters Jenny S. Pavita Howe Cheri Hennessy Juliet Hart Itziar"},"entityUrn":"urn:li:ugcPost:7171897446371840001"}}},{"createdAt":1709842200000,"insightId":"0f19a6ba-e430-4c47-aecc-61649e842e74","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E22AQGrS4WWU4uINg\/feedshare-shrink_2048_1536\/0\/1709842231543?e=1720051200&v=beta&t=fMxZljJN8E6UU1jO3PNVHdXyWoUqATa0u8N6vRzL-Iw"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7171598117480443904","threadUrn":"urn:li:activity:7171598117480443904","reactionsCount":2,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7171598114083053568","message":{"attributes":[{"start":195,"length":20,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:11025388"}}},{"start":451,"length":24,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:11293735"}}},{"start":760,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:6488966"}}},{"start":773,"length":14,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:228426907"}}},{"start":1480,"length":12,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:3684165"}}},{"start":1493,"length":27,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:21041"}}},{"start":1521,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:2769259"}}},{"start":1532,"length":15,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:159806381"}}},{"start":2162,"length":10,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:2992543"}}},{"start":2395,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:advancedtherapies"}}},{"start":2414,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:cellandgenetherapy"}}},{"start":2434,"length":13,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdelivery"}}},{"start":2448,"length":18,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:precisiononcology"}}},{"start":2467,"length":16,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:drugdevelopment"}}}],"text":"What trends will speed up the journey from bench \ud83e\uddec to bedside \ud83d\udc69\u200d\u2695\ufe0f?\n\nAn older but relevant podcast. I summarized the insights for an easy and read.\n\nPodcast Link in Comments.\n\nGreat program by Drug Discovery World\n\n\ud83e\uddeaWill improved structural chemistry and AI help draw value from SMols in the age of IRA rip currents?\n\nWhile Biologics offers greater patent lives, portfolios can be balanced with adaptable and highly translatable SMOLs. The team at PharmEnable Therapeutics,,= discusses how better 3D molecular targeting and AI-based improved druggability have improved their SMOL platform for better intratumoral specificity. Such advances offer portfolios a balance between advanced biology and SMOls with favorable manufacturing, access, and compliance.  Peter Curran Jelena Aleksic\n\n\ud83d\udd2cCan Single Cell Gene Expression meaningfully accelerate clinical translational research?\n\nscRNA\u2010seq has become a widely used tool vs bulk sequencing of the entire transcriptome.Single Cell NA sequencing is an improvement over current methods that restrict analysis to a limited number of cells. scRNA-seq can give access to tumor heterogeneity in response to therapeutics\u2014the ability to see each tree in the forest! \ud83c\udf33\n\nThis allows for gene expression analysis between resistant and sensitive groups to be identified, allowing us to understand potential mechanisms of resistance. This could help scale-up clinical translation significantly when coupled with NGS and advanced diagnostics.  10x Genomics Integrated DNA Technologies Dina Finan Nicholas Downey\n\n\u2695\ufe0f\ud83d\ude37New Drug Modalities in the wake of the pandemic?\n\nmRNA therapeutics present versatility and flexibility across diseases. There are 88 DNA\\RNA based therapeutic trials in the clinic with 23 in registration trials! When you combine these therapies with lipid nanoparticle delivery, you can further promote sustained bioavailability. \ud83d\ude9a \n\nThis multibillion-dollar industry was further propelled by the COVID-19, when contract development and manufacturing organizations (CDMOs) rapidly produced billions of urgently needed vaccine doses. They could play a significant role in advancing mRNA product modalities. \u00a0James Park\n\nHere you go! \n\nI hope you enjoyed this summary of the latest developments that could propel the bench to clinical trials and innovation in a highly competitive and growing Biotechnology and oncology therapeutics space. \n\n#advancedtherapies #cellandgenetherapy #drugdelivery #precisiononcology #drugdevelopment \n"},"entityUrn":"urn:li:share:7171598114083053568"}}},{"createdAt":1709813160000,"insightId":"788f0bdf-ad52-4b86-b063-c0d7578ac0de","activityUnion":{"postActivity":{"contentSummaryUnion":{"referenceContentSummary":{"entityUrn":"urn:li:poll:7171476368046575617"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7171476369187553282","threadUrn":"urn:li:ugcPost:7171476369187553282","reactionsCount":2,"commentsCount":2,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171476369187553282","message":{"attributes":[],"text":"\ud83d\udcc8 With half a dozen Biotech IPOs by Valentine's Day \u2764\ufe0f and another couple dozen in the wait-and-see-zone, what is your opinion on trending Biotech IPOs? "},"entityUrn":"urn:li:ugcPost:7171476369187553282"}}},{"createdAt":1716922560000,"insightId":"1bcc82ab-5095-4814-a360-d44306ba2196","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(articleSegment:(urn:li:linkedInArticle:7199831657401450499,7199831659506978816),7201295353185267715)","threadUrn":"urn:li:articleSegment:(urn:li:linkedInArticle:7199831657401450499,7199831659506978816)","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Someone had once told me, and this is not my quote, but it's a good one : \" Innovation happens when you bring someone in who knows something very different from what you do\".\n\nYou might consider being a contractor temporarily or longer -term by advancing client goals via fresh & innovative perspectives from multiple areas. This is rooted in performance agility so that you can find a solution to the problem that has been admired for too long.\n\nTake Cell and Gene therapy space for instance. A long time heme space play, from the 2024 ASCGT, we saw Solid tumors targeted by 41 (37%) and blood cancers targeted by 33 (29%) of the assets! This will require solid tumor and PMx skills and talent."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:articleSegment:(urn:li:linkedInArticle:7199831657401450499,7199831659506978816)"}}},{"createdAt":1716921060000,"insightId":"98c2fb12-2cb9-4084-8c4d-481a2e20bff6","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7201258432769712128,7201288934159433729)","threadUrn":"urn:li:activity:7201258432769712128","reactionsCount":2,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":395,"length":17,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:76204440"}}},{"start":435,"length":18,"value":{"com.linkedin.common.CompanyAttributedEntity":{"company":"urn:li:company:97467082"}}}],"text":"Joya Dass, I am not speaking on behalf of Naseem in saying this, but here is my opinion - \"the network\". It is disproportionately difficult for women to divert their time as well as gain access to the bigger piece of the inner-circle network. One way to address this is to increase the number of women #VCs and #investors in the power circle. This is something I see happening via firms such as Emmeline Ventures and movements such as Show Her The Money. Your net-worth is your #network."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7201258432769712128"}}},{"createdAt":1716646020000,"insightId":"46e47c13-b484-4534-82fa-af53b95aa402","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7200118573711699968,7200135504888033280)","threadUrn":"urn:li:activity:7200118573711699968","reactionsCount":2,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Nearly 100 Million people in the US have medical debt . Cost of care certainly goes beyond the drug price .https:\/\/www.npr.org\/2023\/12\/10\/1198909604\/the-unbearable-weight-of-medical-debt"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7200118573711699968"}}},{"createdAt":1716640680000,"insightId":"a78be33b-6495-4af5-b314-df78c940c1d0","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7199953032480964608,7200112979466481664)","threadUrn":"urn:li:activity:7199953032480964608","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"These are indications for the definitive clinical impact as we progress towards varied testing options (across tumors), combined with policy enhancements \ud83e\uddea\ud83e\uddec"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7199953032480964608"}}},{"createdAt":1716638100000,"insightId":"21f48cc5-3e97-40e4-871e-3c20d85da1b9","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7199731010417115138,7200102286151364608)","threadUrn":"urn:li:ugcPost:7199731010417115138","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:959068871"}}}],"text":"Zaryab Ahmad it\u2019s a great way to also assess staff augmentation needs and job descriptions. The hiring process is also hurting and complicated in a growing environment where multiple skills sets are required"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7199731010417115138"}}},{"createdAt":1716638040000,"insightId":"b0f9af1e-25d6-4e44-bf77-74ff261f9b56","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7198993060603514880,7200101959859601408)","threadUrn":"urn:li:activity:7198993060603514880","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[{"start":0,"length":12,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:233341653"}}}],"text":"Nina Schwark absolutely! Fractional engagement  is also a great way to risk mitigate and streamline spends while assessing organization\u2019s mid to longer term growth requirements"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7198993060603514880"}}},{"createdAt":1716244440000,"insightId":"f5be9b26-3e9c-4a05-818e-1ba2e3e16642","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7198434818731163648,7198450971402731521)","threadUrn":"urn:li:activity:7198434818731163648","reactionsCount":0,"commentsCount":1,"canComment":true},"commentary":{"attributes":[{"start":46,"length":17,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:344297612"}}},{"start":64,"length":22,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:367949527"}}},{"start":87,"length":15,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:478963904"}}},{"start":103,"length":9,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:17826375"}}},{"start":113,"length":13,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:3234835"}}},{"start":127,"length":21,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:29488005"}}}],"text":"Wonderful reminder, refresher and informative Ryan P. O'Connell Katya Mantrova, MD PhD Sarah Spotswood Aileen H. Michael Wiley Sandra Powell-Elliott"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7198434818731163648"}}}]}